Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Apr;27(14):2200275.
doi: 10.2807/1560-7917.ES.2022.27.14.2200275.

HIV-1-infection in a man who has sex with men despite self-reported excellent adherence to pre-exposure prophylaxis, the Netherlands, August 2021: be alert to emtricitabine/tenofovir-resistant strain transmission

Jeffrey Cd Koole  1 , Feline de la Court  1 , Matthijs Ra Welkers  1   2 , Kenneth Yap  1 , Janneke E Stalenhoef  3 , Suzanne Jurriaans  2 , Henry Jc de Vries  1   4 , Eline Lm Op de Coul  5 , Maria Prins  1   6 , Elske Hoornenborg  1
Affiliations

HIV-1-infection in a man who has sex with men despite self-reported excellent adherence to pre-exposure prophylaxis, the Netherlands, August 2021: be alert to emtricitabine/tenofovir-resistant strain transmission

Jeffrey Cd Koole et al. Euro Surveill. 2022 Apr.

Abstract

In August 2021, a man who has sex with men was diagnosed with HIV-1 infection despite using event-driven pre-exposure prophylaxis for over 2 years with self-reported excellent adherence. Sequencing identified resistance-associated mutations (RAM) M184V and K65R, conferring resistance to emtricitabine and tenofovir, and RAM V108I and E138A. Background RAM prevalence was two of 164 (1.2%) new HIV diagnoses in Amsterdam (2017-19). We reiterate the need for frequent HIV testing among PrEP users and additional testing in case of symptoms.

Keywords: HIV; HIV pre-exposure prophylaxis; antiretroviral drug resistance; case report; diagnostics; genomic surveillance; prevention.

PubMed Disclaimer

Conflict of interest statement

Conflict of interest: None declared.

Figures

Figure
Figure
Timeline of reported sex acts, healthcare events from last negative HIV-test until antiretroviral therapy initiation, and PrEP failure in a man who has sex with men with self-reported excellent PrEP adherence, the Netherlands, August 2021
See this image and copyright information in PMC

References

    1. Fonner VA, Dalglish SL, Kennedy CE, Baggaley R, O’Reilly KR, Koechlin FM, et al. Effectiveness and safety of oral HIV preexposure prophylaxis for all populations. AIDS. 2016;30(12):1973-83. 10.1097/QAD.0000000000001145 - DOI - PMC - PubMed
    1. Molina JM, Capitant C, Spire B, Pialoux G, Cotte L, Charreau I, et al. On-demand preexposure prophylaxis in men at high risk for HIV-1 infection. N Engl J Med. 2015;373(23):2237-46. 10.1056/NEJMoa1506273 - DOI - PubMed
    1. Cohen SE, Sachdev D, Lee SA, Scheer S, Bacon O, Chen MJ, et al. Acquisition of tenofovir-susceptible, emtricitabine-resistant HIV despite high adherence to daily pre-exposure prophylaxis: a case report. Lancet HIV. 2018;S2352-3018(18)30288-1. - PMC - PubMed
    1. Colby DJ, Kroon E, Sacdalan C, Gandhi M, Grant RM, Phanuphak P, et al. Acquisition of multidrug-resistant human immunodeficiency virus type 1 infection in a patient taking preexposure prophylaxis. Clin Infect Dis. 2018;67(6):962-4. 10.1093/cid/ciy321 - DOI - PMC - PubMed
    1. Knox DC, Anderson PL, Harrigan PR, Tan DH. Multidrug-resistant HIV-1 Infection despite preexposure prophylaxis. N Engl J Med. 2017;376(5):501-2. 10.1056/NEJMc1611639 - DOI - PubMed